{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:03:20Z","timestamp":1789560200315,"version":"build-2803163510"},"reference-count":144,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IRDR"],"published-print":{"date-parts":[[2017]]},"DOI":"10.5582\/irdr.2017.01005","type":"journal-article","created":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T09:11:08Z","timestamp":1487668268000},"page":"6-20","source":"Crossref","is-referenced-by-count":99,"title":["Novel and emerging therapies in the treatment of recessive dystrophic epidermolysis bullosa"],"prefix":"10.5582","volume":"6","author":[{"given":"Ellie","family":"Rashidghamat","sequence":"first","affiliation":[{"name":"St. John's Institute of Dermatology, King's College London"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"McGrath","sequence":"additional","affiliation":[{"name":"St. John's Institute of Dermatology, King's College London"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Fine JD, Bruckner-Tuderman L, Eady RA, et al. Inherited epidermolysis bullosa: Updated recommendations on diagnosis and classification. J Am Acad Dermatol. 2014; 70:1103-1126.","DOI":"10.1016\/j.jaad.2014.01.903"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Hsu CK, Wang SP, Lee JY, McGrath JA. Treatment of hereditary epidermolysis bullosa: Updates and future prospects. Am J Clin Dermatol. 2014; 15:1-6.","DOI":"10.1007\/s40257-013-0059-z"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Sakai LY, Keene DR, Morris NP, Burgeson RE. Type VII collagen is a major structural component of anchoring fibrils. J Cell Biol. 1986; 103:1577-1586.","DOI":"10.1083\/jcb.103.4.1577"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Shimizu H, McGrath JA, Christiano AM, Nishikawa T, Uitto J. Molecular basis of recessive dystrophic epidermolysis bullosa: Genotype\/phenotype correlation in a case of moderate clinical severity. J Invest Dermatol. 1996; 106:119-124.","DOI":"10.1111\/1523-1747.ep12329600"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Dang N, Murrell DF. Mutation analysis and characterization of COL7A1 mutations in dystrophic epidermolysis bullosa. Exp Dermatol. 2008; 17:553-568.","DOI":"10.1111\/j.1600-0625.2008.00723.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Leigh IM, Eady RA, Heagerty AH, Purkis PE, Whitehead PA, Burgeson RE. Type VII collagen is a normal component of epidermal basement membrane, which shows altered expression in recessive dystrophic epidermolysis bullosa. J Invest Dermatol. 1988; 90:639-642.","DOI":"10.1111\/1523-1747.ep12560795"},{"key":"7","unstructured":"7. Denyer J. Managing pain in children with epidermolysis bullosa. Nurs Times. 2012; 108:21-23."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Fine JD, Mellerio JE. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: Part II. Other organs. J Am Acad Dermatol. 2009; 61:387-402; quiz 403-404.","DOI":"10.1016\/j.jaad.2009.03.053"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Goldschneider KR, Good J, Harrop E, Liossi C, Lynch-Jordan A, Martinez AE, Maxwell LG, Stanko-Lopp D, Dystrophic Epidermolysis Bullosa Research Association I. Pain care for patients with epidermolysis bullosa: Best care practice guidelines. BMC Med. 2014; 12:178.","DOI":"10.1186\/s12916-014-0178-2"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Freeman EB, Koglmeier J, Martinez AE, Mellerio JE, Haynes L, Sebire NJ, Lindley KJ, Shah N. Gastrointestinal complications of epidermolysis bullosa in children. Br J Dermatol. 2008; 158:1308-1314.","DOI":"10.1111\/j.1365-2133.2008.08507.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Chiu YK, Prendiville JS, Bennett SM, Montgomery CJ, Oberlander TF. Pain management of junctional epidermolysis bullosa in an 11-year-old boy. Pediatr Dermatol. 1999; 16:465-468.","DOI":"10.1046\/j.1525-1470.1999.00120.x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. van Scheppingen C, Lettinga AT, Duipmans JC, Maathuis CG, Jonkman MF. Main problems experienced by children with epidermolysis bullosa: A qualitative study with semi-structured interviews. Acta Derm Venereol. 2008; 88:143-150.","DOI":"10.2340\/00015555-0376"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Danial C, Adeduntan R, Gorell ES, Lucky AW, Paller AS, Bruckner A, Pope E, Morel KD, Levy ML, Li S, Gilmore ES, Lane AT. Prevalence and characterization of pruritus in epidermolysis bullosa. Pediatr Dermatol. 2015; 32:53-59.","DOI":"10.1111\/pde.12391"},{"key":"14","unstructured":"14. Wright JT, Fine JD, Johnson L. Dental caries risk in hereditary epidermolysis bullosa. Pediatr Dent. 1994; 16:427-432."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Fortuna G, Aria M, Cepeda-Valdes R, Pollio A, Moreno-Trevino MG, Salas-Alanis JC. Clinical features of gingival lesions in patients with dystrophic epidermolysis bullosa: A cross-sectional study. Aust Dent J. 2015; 60:18-23.","DOI":"10.1111\/adj.12264"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Crawford EG, Jr, Burkes EJ, Jr, Briggaman RA. Hereditary epidermolysis bullosa: Oral manifestations and dental therapy. Oral Surg Oral Med Oral Pathol. 1976; 42:490-500.","DOI":"10.1016\/0030-4220(76)90296-6"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Wright JT. Comprehensive dental care and general anesthetic management of hereditary epidermolysis bullosa. A review of fourteen cases. Oral Surg Oral Med Oral Pathol. 1990; 70:573-578.","DOI":"10.1016\/0030-4220(90)90401-D"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Marini I, Vecchiet F. Sucralfate: A help during oral management in patients with epidermolysis bullosa. J Periodontol. 2001; 72:691-695.","DOI":"10.1902\/jop.2001.72.5.691"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Colomb V, Bourdon-Lannoy E, Lambe C, Sauvat F, Hadj Rabia S, Teillac D, De Prost Y, Bodemer C. Nutritional outcome in children with severe generalized recessive dystrophic epidermolysis bullosa: A short- and long-term evaluation of gastrostomy and enteral feeding. Br J Dermatol. 2012; 166:354-361.","DOI":"10.1111\/j.1365-2133.2011.10592.x"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Fewtrell MS, Allgrove J, Gordon I, Brain C, Atherton D, Harper J, Mellerio JE, Martinez AE. Bone mineralization in children with epidermolysis bullosa. Br J Dermatol. 2006; 154:959-962.","DOI":"10.1111\/j.1365-2133.2005.07123.x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Martinez AE, Mellerio JE. Osteopenia and osteoporosis in epidermolysis bullosa. Dermatol Clin. 2010; 28:353-355.","DOI":"10.1016\/j.det.2010.01.006"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Martinez AE, Allgrove J, Brain C. Growth and pubertal delay in patients with epidermolysis bullosa. Dermatol Clin. 2010; 28:357-359.","DOI":"10.1016\/j.det.2010.01.007"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Pillay E. Epidermolysis bullosa. Part 1: Causes, presentation and complications. Br J Nurs. 2008; 17:292-296.","DOI":"10.12968\/bjon.2008.17.5.28824"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Pope E, Lara-Corrales I, Mellerio J, Martinez A, Schultz G, Burrell R, Goodman L, Coutts P, Wagner J, Allen U, Sibbald G. A consensus approach to wound care in epidermolysis bullosa. J Am Acad Dermatol. 2012; 67:904-917.","DOI":"10.1016\/j.jaad.2012.01.016"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Marin-Bertolin S, Amaya Valero JV, Neira Gimenez C, Marquina Vila P, Amorrortu-Velayos J. Surgical management of hand contractures and pseudosyndactyly in dystrophic epidermolysis bullosa. Ann Plast Surg. 1999; 43:555-559.","DOI":"10.1097\/00000637-199911000-00017"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Bernardis C, Box R. Surgery of the hand in recessive dystrophic epidermolysis bullosa. Dermatol Clin. 2010; 28:335-341, xi.","DOI":"10.1016\/j.det.2010.01.013"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. McGrath JA, O&apos;Grady A, Mayou BJ, Eady RA. Mitten deformity in severe generalized recessive dystrophic epidermolysis bullosa: Histological, immunofluorescence, and ultrastructural study. J Cutan Pathol. 1992; 19:385-389.","DOI":"10.1111\/j.1600-0560.1992.tb00610.x"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Terrill PJ, Mayou BJ, Pemberton J. Experience in the surgical management of the hand in dystrophic epidermolysis bullosa. Br J Plast Surg. 1992; 45:435-442.","DOI":"10.1016\/0007-1226(92)90207-E"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Fine JD, Johnson LB, Weiner M, Li KP, Suchindran C. Epidermolysis bullosa and the risk of life-threatening cancers: The National EB Registry experience, 1986-2006. J Am Acad Dermatol. 2009; 60:203-211.","DOI":"10.1016\/j.jaad.2008.09.035"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Tomita Y, Sato-Matsumura KC, Sawamura D, Matsumura T, Shimizu H. Simultaneous occurrence of three squamous cell carcinomas in a recessive dystrophic epidermolysis bullosa patient. Acta Derm Venereol. 2003; 83:225-226.","DOI":"10.1080\/00015550310007283"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Mellerio JE, Robertson SJ, Bernardis C, et al. Management of cutaneous squamous cell carcinoma in patients with epidermolysis bullosa: Best clinical practice guidelines. Br J Dermatol. 2016; 174:56-67.","DOI":"10.1111\/bjd.14104"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Lentz SR, Raish RJ, Orlowski EP, Marion JM. Squamous cell carcinoma in epidermolysis bullosa. Treatment with systemic chemotherapy. Cancer. 1990; 66:1276-1278.","DOI":"10.1002\/1097-0142(19900915)66:6<1276::AID-CNCR2820660629>3.0.CO;2-A"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Wechsler HL, Krugh FJ, Domonkos AN, Scheen SR, Davidson CL, Jr. Polydysplastic epidermolysis bullosa and deelopment of epidermal neoplasms. Arch Dermatol. 1970; 102:374-380.","DOI":"10.1001\/archderm.1970.04000100022006"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Mallipeddi R. Epidermolysis bullosa and cancer. Clin Exp Dermatol. 2002; 27:616-623.","DOI":"10.1046\/j.1365-2230.2002.01130.x"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Schwartz RA, Birnkrant AP, Rubenstein DJ, Kim U, Burgess GH, Stoll HL, Jr, Chai SW, Southwick GJ, Milgrom H. Squamous cell carcinoma in dominant type epidermolysis bullosa dystrophica. Cancer. 1981; 47:615-620.","DOI":"10.1002\/1097-0142(19810201)47:3<615::AID-CNCR2820470332>3.0.CO;2-T"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Gebbia V, Giuliani F, Valori VM, Agueli R, Colucci G, Maiello E. Cetuximab in squamous cell head and neck carcinomas. Ann Oncol. 2007; 18 Suppl 6:vi5-7.","DOI":"10.1093\/annonc\/mdm215"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Sharafinski ME, Ferris RL, Ferrone S, Grandis JR. Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck. 2010; 32:1412-1421.","DOI":"10.1002\/hed.21365"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Maubec E, Petrow P, Scheer-Senyarich I, et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol. 2011; 29:3419-3426.","DOI":"10.1200\/JCO.2010.34.1735"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Kim M, Li M, Intong LR, Tran K, Melbourne W, Marucci D, Bucci J, de Souza P, Mallesara G, Murrell DF. Use of cetuximab as an adjuvant agent to radiotherapy and surgery in recessive dystrophic epidermolysis bullosa with squamous cell carcinoma. Br J Dermatol. 2013; 169:208-210.","DOI":"10.1111\/bjd.12272"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Arnold AW, Bruckner-Tuderman L, Zuger C, Itin PH. Cetuximab therapy of metastasizing cutaneous squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa. Dermatology. 2009; 219:80-83.","DOI":"10.1159\/000218714"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Fine JD, Johnson LB, Weiner M, Stein A, Suchindran C. Chemoprevention of squamous cell carcinoma in recessive dystrophic epidermolysis bullosa: Results of a phase 1 trial of systemic isotretinoin. J Am Acad Dermatol. 2004; 50:563-571.","DOI":"10.1016\/j.jaad.2003.08.008"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Shinkuma S, Sawamura D, Fujita Y, Kawasaki H, Nakamura H, Inoie M, Nishie W, Shimizu H. Long-term follow-up of cultured epidermal autograft in a patient with recessive dystrophic epidermolysis bullosa. Acta Derm Venereol. 2014; 94:98-99.","DOI":"10.2340\/00015555-1592"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Fivenson DP, Scherschun L, Cohen LV. Apligraf in the treatment of severe mitten deformity associated with recessive dystrophic epidermolysis bullosa. Plast Reconstr Surg. 2003; 112:584-588.","DOI":"10.1097\/01.PRS.0000070730.95956.01"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Falabella AF, Valencia IC, Eaglstein WH, Schachner LA. Tissue-engineered skin (Apligraf) in the healing of patients with epidermolysis bullosa wounds. Arch Dermatol. 2000; 136:1225-1230.","DOI":"10.1001\/archderm.136.10.1225"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Hasegawa T, Suga Y, Mizoguchi M, Ikeda S, Ogawa H, Kubo K, Matsui H, Kagawa S, Kuroyanagi Y. Clinical trial of allogeneic cultured dermal substitute for the treatment of intractable skin ulcers in 3 patients with recessive dystrophic epidermolysis bullosa. J Am Acad Dermatol. 2004; 50:803-804.","DOI":"10.1016\/j.jaad.2003.08.013"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Natsuga K, Sawamura D, Goto M, Homma E, Goto-Ohguchi Y, Aoyagi S, Akiyama M, Kuroyanagi Y, Shimizu H. Response of intractable skin ulcers in recessive dystrophic epidermolysis bullosa patients to an allogeneic cultured dermal substitute. Acta Derm Venereol. 2010; 90:165-169.","DOI":"10.2340\/00015555-0776"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Falabella AF, Schachner LA, Valencia IC, Eaglstein WH. The use of tissue-engineered skin (Apligraf) to treat a newborn with epidermolysis bullosa. Arch Dermatol. 1999; 135:1219-1222.","DOI":"10.1001\/archderm.135.10.1219"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Niknejad H, Peirovi H, Jorjani M, Ahmadiani A, Ghanavi J, Seifalian AM. Properties of the amniotic membrane for potential use in tissue engineering. Eur Cell Mater. 2008; 15:88-99.","DOI":"10.22203\/eCM.v015a07"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Lo V, Lara-Corrales I, Stuparich A, Pope E. Amniotic membrane grafting in patients with epidermolysis bullosa with chronic wounds. J Am Acad Dermatol. 2010; 62:1038-1044.","DOI":"10.1016\/j.jaad.2009.02.048"},{"key":"50","unstructured":"50. Martinez Pardo ME, Reyes Frias ML, Ramos Duron LE, Gutierrez Salgado E, Gomez JC, Marin MA, Luna Zaragoza D. Clinical application of amniotic membranes on a patient with epidermolysis bullosa. Ann Transplant. 1999; 4:68-73."},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Gibbons GW. Grafix\u00ae, a cryopreserved placental membrane, for the treatment of chronic\/stalled wounds. Adv Wound Care (New Rochelle). 2015; 4:534-544.","DOI":"10.1089\/wound.2015.0647"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Nevala-Plagemann C, Lee C, Tolar J. Placenta-based therapies for the treatment of epidermolysis bullosa. Cytotherapy. 2015; 17:786-795.","DOI":"10.1016\/j.jcyt.2015.03.006"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Lavery LA, Fulmer J, Shebetka KA, Regulski M, Vayser D, Fried D, Kashefsky H, Owings TM, Nadarajah J; Grafix Diabetic Foot Ulcer Study Group. The efficacy and safety of Grafix\u00ae for the treatment of chronic diabetic foot ulcers: Results of a multi-centre, controlled, randomised, blinded, clinical trial. Int Wound J. 2014; 11:554-560.","DOI":"10.1111\/iwj.12329"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Dagregorio G, Guillet G. Artificial skin as a valuable adjunct to surgical treatment of a large squamous cell carcinoma in a patient with epidermolysis bullosa. Dermatol Surg. 2005; 31:474-476.","DOI":"10.1097\/00042728-200504000-00018"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Wiegand C, Schonfelder U, Abel M, Ruth P, Kaatz M, Hipler UC. Protease and pro-inflammatory cytokine concentrations are elevated in chronic compared to acute wounds and can be modulated by collagen type I in vitro. Arch Dermatol Res. 2010; 302:419-428.","DOI":"10.1007\/s00403-009-1011-1"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Gorell ES, Leung TH, Khuu P, Lane AT. Purified type I collagen wound matrix improves chronic wound healing in patients with recessive dystrophic epidermolysis bullosa. Pediatr Dermatol. 2015; 32:220-225.","DOI":"10.1111\/pde.12492"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Fine JD. Epidermolysis bullosa: A genetic disease of altered cell adhesion and wound healing, and the possible clinical utility of topically applied thymosin beta4. Ann N Y Acad Sci. 2007; 1112:396-406.","DOI":"10.1196\/annals.1415.017"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Margolis DJ, Morris LM, Papadopoulos M, Weinberg L, Filip JC, Lang SA, Vaikunth SS, Crombleholme TM. Phase I study of H5.020CMV.PDGF-beta to treat venous leg ulcer disease. Mol Ther. 2009; 17:1822-1829.","DOI":"10.1038\/mt.2009.169"},{"key":"59","unstructured":"59. Ma C, Hernandez MA, Kirkpatrick VE, Liang LJ, Nouvong AL, Gordon, II. Topical platelet-derived growth factor vs placebo therapy of diabetic foot ulcers offloaded with windowed casts: A randomized, controlled trial. Wounds. 2015; 27:83-91."},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Pearson RW. Studies on the pathogenesis of epidermolysis bullosa. J Invest Dermatol. 1962; 39:551-575.","DOI":"10.1038\/jid.1962.156"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Bauer EA, Cooper TW, Tucker DR, Esterly NB. Phenytoin therapy of recessive dystrophic epidermolysis bullosa. Clinical trial and proposed mechanism of action on collagenase. N Engl J Med. 1980; 303:776-781.","DOI":"10.1056\/NEJM198010023031402"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Caldwell-Brown D, Stern RS, Lin AN, Carter DM. Lack of efficacy of phenytoin in recessive dystrophic epidermolysis bullosa. Epidermolysis Bullosa Study Group. N Engl J Med. 1992; 327:163-167.","DOI":"10.1056\/NEJM199207163270305"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. White JE. Minocycline for dystrophic epidermolysis bullosa. Lancet. 1989; 1:966.","DOI":"10.1016\/S0140-6736(89)92555-5"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. Golub LM, Wolff M, Lee HM, McNamara TF, Ramamurthy NS, Zambon J, Ciancio S. Further evidence that tetracyclines inhibit collagenase activity in human crevicular fluid and from other mammalian sources. J Periodontal Res. 1985; 20:12-23.","DOI":"10.1111\/j.1600-0765.1985.tb00405.x"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65. Lettner T, Lang R, Bauer JW, Wally V. Increased levels of matrix metalloproteinase-9 and interleukin-8 in blister fluids of dystrophic and junctional epidermolysis bullosa patients. J Eur Acad Dermatol Venereol. 2015; 29:396-398.","DOI":"10.1111\/jdv.12399"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Leung J, Kuzel P, Kurian A, Brassard A. A Case of Dominant Dystrophic Epidermolysis Bullosa Responding Well to an Old Medication. JAMA Dermatol. 2015; 151:1264-1265.","DOI":"10.1001\/jamadermatol.2015.1791"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67. Esterly NB, Furey NL, Flanagan LE. The effect of antimicrobial agents on leukocyte chemotaxis. J Invest Dermatol. 1978; 70:51-55.","DOI":"10.1111\/1523-1747.ep12543487"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68. Lara-Corrales I, Parkin PC, Stephens D, Hamilton J, Koren G, Weinstein M, Sibbald RG, Pope E. The efficacy of trimethoprim in wound healing of patients with epidermolysis bullosa: A feasibility trial. J Am Acad Dermatol. 2012; 66:264-270.","DOI":"10.1016\/j.jaad.2010.01.047"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69. Changotade SI, Assoumou A, Gueniche F, Fioretti F, Seguier S, de Prost Y, Bodemer C, Godeau G, Senni K. Epigallocatechin gallate&apos;s protective effect against MMP7 in recessive dystrophic epidermolysis bullosa patients. J Invest Dermatol. 2007; 127:821-828.","DOI":"10.1038\/sj.jid.5700645"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70. Chiaverini C, Roger C, Fontas E, Bourrat E, Bourdon-Lanoy E, Labreze C, Mazereeuw J, Vabres P, Bodemer C, Lacour JP. Oral epigallocatechin-3-gallate for treatment of dystrophic epidermolysis bullosa: A multicentre, randomized, crossover, double-blind, placebo-controlled clinical trial. Orphanet J Rare Dis. 2016; 11:31.","DOI":"10.1186\/s13023-016-0411-5"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71. del-Rio E. Prevention of blisters in dystrophic recessive epidermolysis bullosa with cyclosporine. J Am Acad Dermatol. 1993; 29:1038-1039.","DOI":"10.1016\/S0190-9622(08)82040-3"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72. El-Darouti MA, Fawzy MM, Amin IM, Abdel Hay RM, Hegazy RA, Abdel Halim DM. Mycophenolate mofetil: A novel immunosuppressant in the treatment of dystrophic epidermolysis bullosa, a randomized controlled trial. J Dermatolog Treat. 2013; 24:422-426.","DOI":"10.3109\/09546634.2013.768327"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73. Gubinelli E, Angelo C, Pacifico V. A case of dystrophic epidermolysis bullosa improved with etanercept for concomitant psoriatic arthritis. Am J Clin Dermatol. 2010; 11 Suppl 1:53-54.","DOI":"10.2165\/1153427-S0-000000000-00000"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74. Fine JD, Manes B, Frangoul H. Systemic granulocyte colony-stimulating factor (G-CSF) enhances wound healing in dystrophic epidermolysis bullosa (DEB): Results of a pilot trial. J Am Acad Dermatol. 2015; 73:56-61.","DOI":"10.1016\/j.jaad.2015.04.015"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75. Fritsch A, Loeckermann S, Kern JS, Braun A, Bosl MR, Bley TA, Schumann H, von Elverfeldt D, Paul D, Erlacher M, Berens von Rautenfeld D, Hausser I, Fassler R, Bruckner-Tuderman L. A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy. J Clin Invest. 2008; 118:1669-1679.","DOI":"10.1172\/JCI34292"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76. Nystrom A, Thriene K, Mittapalli V, Kern JS, Kiritsi D, Dengjel J, Bruckner-Tuderman L. Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms. EMBO Mol Med. 2015; 7:1211-1228.","DOI":"10.15252\/emmm.201505061"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77. Odorisio T, Di Salvio M, Orecchia A, Di Zenzo G, Piccinni E, Cianfarani F, Travaglione A, Uva P, Bellei B, Conti A, Zambruno G, Castiglia D. Monozygotic twins discordant for recessive dystrophic epidermolysis bullosa phenotype highlight the role of TGF-beta signalling in modifying disease severity. Hum Mol Genet. 2014; 23:3907-3922.","DOI":"10.1093\/hmg\/ddu102"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78. Tamai K, Yamazaki T, Chino T, et al. PDGFRalpha-positive cells in bone marrow are mobilized by high mobility group box 1 (HMGB1) to regenerate injured epithelia. Proc Natl Acad Sci U S A. 2011; 108:6609-6614.","DOI":"10.1073\/pnas.1016753108"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79. Stanley JR, Rubinstein N, Klaus-Kovtun V. Epidermolysis bullosa acquisita antigen is synthesized by both human keratinocytes and human dermal fibroblasts. J Invest Dermatol. 1985; 85:542-545.","DOI":"10.1111\/1523-1747.ep12277377"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80. Wong T, Gammon L, Liu L, Mellerio JE, Dopping-Hepenstal PJ, Pacy J, Elia G, Jeffery R, Leigh IM, Navsaria H, McGrath JA. Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa. J Invest Dermatol. 2008; 128:2179-2189.","DOI":"10.1038\/jid.2008.78"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81. Kern JS, Loeckermann S, Fritsch A, Hausser I, Roth W, Magin TM, Mack C, Muller ML, Paul O, Ruther P, Bruckner-Tuderman L. Mechanisms of fibroblast cell therapy for dystrophic epidermolysis bullosa: High stability of collagen VII favors long-term skin integrity. Mol Ther. 2009; 17:1605-1615.","DOI":"10.1038\/mt.2009.144"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82. Nagy N, Almaani N, Tanaka A, Lai-Cheong JE, Techanukul T, Mellerio JE, McGrath JA. HB-EGF induces COL7A1 expression in keratinocytes and fibroblasts: Possible mechanism underlying allogeneic fibroblast therapy in recessive dystrophic epidermolysis Bullosa. J Invest Dermatol. 2011; 131:1771-1774.","DOI":"10.1038\/jid.2011.85"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83. Venugopal SS, Yan W, Frew JW, Cohn HI, Rhodes LM, Tran K, Melbourne W, Nelson JA, Sturm M, Fogarty J, Marinkovich MP, Igawa S, Ishida-Yamamoto A, Murrell DF. A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa. J Am Acad Dermatol. 2013; 69:898-908.","DOI":"10.1016\/j.jaad.2013.08.014"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84. Petrof G, Martinez-Queipo M, Mellerio JE, Kemp P, McGrath JA. Fibroblast cell therapy enhances initial healing in recessive dystrophic epidermolysis bullosa wounds: Results of a randomized, vehicle-controlled trial. Br J Dermatol. 2013; 169:1025-1033.","DOI":"10.1111\/bjd.12599"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85. Najar M, Raicevic G, Boufker HI, Fayyad Kazan H, De Bruyn C, Meuleman N, Bron D, Toungouz M, Lagneaux L. Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: Combined comparison of adipose tissue, Wharton&apos;s Jelly and bone marrow sources. Cell Immunol. 2010; 264:171-179.","DOI":"10.1016\/j.cellimm.2010.06.006"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86. Montesinos JJ, Flores-Figueroa E, Castillo-Medina S, Flores-Guzman P, Hernandez-Estevez E, Fajardo-Orduna G, Orozco S, Mayani H. Human mesenchymal stromal cells from adult and neonatal sources: Comparative analysis of their morphology, immunophenotype, differentiation patterns and neural protein expression. Cytotherapy. 2009; 11:163-176.","DOI":"10.1080\/14653240802582075"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87. Conget P, Rodriguez F, Kramer S, Allers C, Simon V, Palisson F, Gonzalez S, Yubero MJ. Replenishment of type VII collagen and re-epithelialization of chronically ulcerated skin after intradermal administration of allogeneic mesenchymal stromal cells in two patients with recessive dystrophic epidermolysis bullosa. Cytotherapy. 2010; 12:429-431.","DOI":"10.3109\/14653241003587637"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88. El-Darouti M, Fawzy M, Amin I, Abdel Hay R, Hegazy R, Gabr H, El Maadawi Z. Treatment of dystrophic epidermolysis bullosa with bone marrow non-hematopoeitic stem cells: A randomized controlled trial. Dermatol Ther. 2016; 29:96-100.","DOI":"10.1111\/dth.12305"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89. Petrof G, Lwin SM, Martinez-Queipo M, Abdul-Wahab A, Tso S, Mellerio JE, Slaper-Cortenbach I, Boelens JJ, Tolar J, Veys P, Ofuya M, Peacock JL, Martinez AE, McGrath JA. Potential of Systemic Allogeneic Mesenchymal Stromal Cell Therapy for Children with Recessive Dystrophic Epidermolysis Bullosa. J Invest Dermatol. 2015; 135:2319-2321.","DOI":"10.1038\/jid.2015.158"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90. Kuhl T, Mezger M, Hausser I, Handgretinger R, Bruckner-Tuderman L, Nystrom A. High local concentrations of intradermal MSCs restore skin integrity and facilitate wound healing in dystrophic epidermolysis bullosa. Mol Ther. 2015; 23:1368-1379.","DOI":"10.1038\/mt.2015.58"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91. Prockop DJ. Repair of tissues by adult stem\/progenitor cells (MSCs): Controversies, myths, and changing paradigms. Mol Ther. 2009; 17:939-946.","DOI":"10.1038\/mt.2009.62"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92. Qi Y, Jiang D, Sindrilaru A, et al. TSG-6 released from intradermally injected mesenchymal stem cells accelerates wound healing and reduces tissue fibrosis in murine full-thickness skin wounds. J Invest Dermatol. 2014; 134:526-537.","DOI":"10.1038\/jid.2013.328"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93. Wang M, Windgassen D, Papoutsakis ET. Comparative analysis of transcriptional profiling of CD3+, CD4+ and CD8+ T cells identifies novel immune response players in T-cell activation. BMC Genomics. 2008; 9:225.","DOI":"10.1186\/1471-2164-9-225"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, Zhao RC, Shi Y. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell. 2008; 2:141-150.","DOI":"10.1016\/j.stem.2007.11.014"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95. Liao Y, Geyer MB, Yang AJ, Cairo MS. Cord blood transplantation and stem cell regenerative potential. Exp Hematol. 2011; 39:393-412.","DOI":"10.1016\/j.exphem.2011.01.002"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96. Liao Y, Itoh M, Yang A, Zhu H, Roberts S, Highet AM, Latshaw S, Mitchell K, van de Ven C, Christiano A, Cairo MS. Human cord blood-derived unrestricted somatic stem cells promote wound healing and have therapeutic potential for patients with recessive dystrophic epidermolysis bullosa. Cell Transplant. 2014; 23:303- 317.","DOI":"10.3727\/096368913X663569"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97. Perdoni C, McGrath JA, Tolar J. Preconditioning of mesenchymal stem cells for improved transplantation efficacy in recessive dystrophic epidermolysis bullosa. Stem Cell Res Ther. 2014; 5:121.","DOI":"10.1186\/scrt511"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98. Tolar J, Ishida-Yamamoto A, Riddle M, McElmurry RT, Osborn M, Xia L, Lund T, Slattery C, Uitto J, Christiano AM, Wagner JE, Blazar BR. Amelioration of epidermolysis bullosa by transfer of wild-type bone marrow cells. Blood. 2009; 113:1167-1174.","DOI":"10.1182\/blood-2008-06-161299"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99. Chino T, Tamai K, Yamazaki T, Otsuru S, Kikuchi Y, Nimura K, Endo M, Nagai M, Uitto J, Kitajima Y, Kaneda Y. Bone marrow cell transfer into fetal circulation can ameliorate genetic skin diseases by providing fibroblasts to the skin and inducing immune tolerance. Am J Pathol. 2008; 173:803-814.","DOI":"10.2353\/ajpath.2008.070977"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100. Wagner JE, Ishida-Yamamoto A, McGrath JA, Hordinsky M, Keene DR, Woodley DT, Chen M, Riddle MJ, Osborn MJ, Lund T, Dolan M, Blazar BR, Tolar J. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N Engl J Med. 2010; 363:629-639.","DOI":"10.1056\/NEJMoa0910501"},{"key":"101","doi-asserted-by":"crossref","unstructured":"101. Tolar J, Wagner JE. Allogeneic blood and bone marrow cells for the treatment of severe epidermolysis bullosa: Repair of the extracellular matrix. Lancet. 2013; 382:1214-1223.","DOI":"10.1016\/S0140-6736(13)61897-8"},{"key":"102","doi-asserted-by":"crossref","unstructured":"102. Iinuma S, Aikawa E, Tamai K, Fujita R, Kikuchi Y, Chino T, Kikuta J, McGrath JA, Uitto J, Ishii M, Iizuka H, Kaneda Y. Transplanted bone marrow-derived circulating PDGFRalpha+ cells restore type VII collagen in recessive dystrophic epidermolysis bullosa mouse skin graft. J Immunol. 2015; 194:1996-2003.","DOI":"10.4049\/jimmunol.1400914"},{"key":"103","doi-asserted-by":"crossref","unstructured":"103. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, Capla JM, Galiano RD, Levine JP, Gurtner GC. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med. 2004; 10:858-864.","DOI":"10.1038\/nm1075"},{"key":"104","doi-asserted-by":"crossref","unstructured":"104. Jonkman MF, Scheffer H, Stulp R, Pas HH, Nijenhuis M, Heeres K, Owaribe K, Pulkkinen L, Uitto J. Revertant mosaicism in epidermolysis bullosa caused by mitotic gene conversion. Cell. 1997; 88:543-551.","DOI":"10.1016\/S0092-8674(00)81894-2"},{"key":"105","doi-asserted-by":"crossref","unstructured":"105. Gostynski A, Deviaene FC, Pasmooij AM, Pas HH, Jonkman MF. Adhesive stripping to remove epidermis in junctional epidermolysis bullosa for revertant cell therapy. Br J Dermatol. 2009; 161:444-447.","DOI":"10.1111\/j.1365-2133.2009.09118.x"},{"key":"106","doi-asserted-by":"crossref","unstructured":"106. Yuen WY, Huizinga J, Jonkman MF. Punch grafting of chronic ulcers in patients with laminin-332-deficient, non-Herlitz junctional epidermolysis bullosa. J Am Acad Dermatol. 2013; 68:93-97.e2.","DOI":"10.1016\/j.jaad.2012.04.012"},{"key":"107","doi-asserted-by":"crossref","unstructured":"107. Pasmooij AM, Pas HH, Deviaene FC, Nijenhuis M, Jonkman MF. Multiple correcting COL17A1 mutations in patients with revertant mosaicism of epidermolysis bullosa. Am J Hum Genet. 2005; 77:727-740.","DOI":"10.1086\/497344"},{"key":"108","doi-asserted-by":"crossref","unstructured":"108. Tolar J, McGrath JA, Xia L, Riddle MJ, Lees CJ, Eide C, Keene DR, Liu L, Osborn MJ, Lund TC, Blazar BR, Wagner JE. Patient-specific naturally gene-reverted induced pluripotent stem cells in recessive dystrophic epidermolysis bullosa. J Invest Dermatol. 2014; 134:1246-1254.","DOI":"10.1038\/jid.2013.523"},{"key":"109","doi-asserted-by":"crossref","unstructured":"109. Umegaki-Arao N, Pasmooij AM, Itoh M, Cerise JE, Guo Z, Levy B, Gostynski A, Rothman LR, Jonkman MF, Christiano AM. Induced pluripotent stem cells from human revertant keratinocytes for the treatment of epidermolysis bullosa. Sci Transl Med. 2014; 6:264ra164.","DOI":"10.1126\/scitranslmed.3009342"},{"key":"110","doi-asserted-by":"crossref","unstructured":"110. Chen M, Kasahara N, Keene DR, Chan L, Hoeffler WK, Finlay D, Barcova M, Cannon PM, Mazurek C, Woodley DT. Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa. Nat Genet. 2002; 32:670-675.","DOI":"10.1038\/ng1041"},{"key":"111","doi-asserted-by":"crossref","unstructured":"111. Woodley DT, Krueger GG, Jorgensen CM, Fairley JA, Atha T, Huang Y, Chan L, Keene DR, Chen M. Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone. J Invest Dermatol. 2003; 121:1021-1028.","DOI":"10.1046\/j.1523-1747.2003.12571.x"},{"key":"112","doi-asserted-by":"crossref","unstructured":"112. Baldeschi C, Gache Y, Rattenholl A, Bouille P, Danos O, Ortonne JP, Bruckner-Tuderman L, Meneguzzi G. Genetic correction of canine dystrophic epidermolysis bullosa mediated by retroviral vectors. Hum Mol Genet. 2003; 12:1897-1905.","DOI":"10.1093\/hmg\/ddg200"},{"key":"113","doi-asserted-by":"crossref","unstructured":"113. Titeux M, Pendaries V, Zanta-Boussif MA, Decha A, Pironon N, Tonasso L, Mejia JE, Brice A, Danos O, Hovnanian A. SIN retroviral vectors expressing COL7A1 under human promoters for ex vivo gene therapy of recessive dystrophic epidermolysis bullosa. Mol Ther. 2010; 18:1509-1518.","DOI":"10.1038\/mt.2010.91"},{"key":"114","doi-asserted-by":"crossref","unstructured":"114. Woodley DT, Keene DR, Atha T, Huang Y, Ram R, Kasahara N, Chen M. Intradermal injection of lentiviral vectors corrects regenerated human dystrophic epidermolysis bullosa skin tissue in vivo. Mol Ther. 2004; 10:318-326.","DOI":"10.1016\/j.ymthe.2004.05.016"},{"key":"115","doi-asserted-by":"crossref","unstructured":"115. Chen M, O&apos;Toole EA, Muellenhoff M, Medina E, Kasahara N, Woodley DT. Development and characterization of a recombinant truncated type VII collagen &quot;minigene&quot;. Implication for gene therapy of dystrophic epidermolysis bullosa. J Biol Chem. 2000; 275:24429-24435.","DOI":"10.1074\/jbc.M003440200"},{"key":"116","doi-asserted-by":"crossref","unstructured":"116. Mavilio F, Pellegrini G, Ferrari S, et al. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat Med. 2006; 12:1397-1402.","DOI":"10.1038\/nm1504"},{"key":"117","doi-asserted-by":"crossref","unstructured":"117. De Rosa L, Carulli S, Cocchiarella F, Quaglino D, Enzo E, Franchini E, Giannetti A, De Santis G, Recchia A, Pellegrini G, De Luca M. Long-term stability and safety of transgenic cultured epidermal stem cells in gene therapy of junctional epidermolysis bullosa. Stem Cell Reports. 2013; 2:1-8.","DOI":"10.1016\/j.stemcr.2013.11.001"},{"key":"118","doi-asserted-by":"crossref","unstructured":"118. Murauer EM, Koller U, Pellegrini G, De Luca M, Bauer JW. Advances in gene\/cell therapy in epidermolysis bullosa. Keio J Med. 2015; 64:21-25.","DOI":"10.2302\/kjm.2014-0013-RE"},{"key":"119","doi-asserted-by":"crossref","unstructured":"119. Siprashvili Z, Nguyen NT, Gorell ES, Loutit K, Khuu P, Furukawa LK, Lorenz HP, Leung TH, Keene DR, Rieger KE, Khavari P, Lane AT, Tang JY, Marinkovich MP. Safety and wound outcomes following genetically corrected autologous epidermal grafts in patients with recessive dystrophic epidermolysis bullosa. JAMA. 2016; 316:1808-1817.","DOI":"10.1001\/jama.2016.15588"},{"key":"120","doi-asserted-by":"crossref","unstructured":"120. Ortiz-Urda S, Thyagarajan B, Keene DR, Lin Q, Fang M, Calos MP, Khavari PA. Stable nonviral genetic correction of inherited human skin disease. Nat Med. 2002; 8:1166-1170.","DOI":"10.1038\/nm766"},{"key":"121","doi-asserted-by":"crossref","unstructured":"121. Ortiz-Urda S, Lin Q, Green CL, Keene DR, Marinkovich MP, Khavari PA. Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue. J Clin Invest. 2003; 111:251-255.","DOI":"10.1172\/JCI200317193"},{"key":"122","doi-asserted-by":"crossref","unstructured":"122. Cutlar L, Zhou D, Hu X, Duarte B, Greiser U, Larcher F, Wang W. A non-viral gene therapy for treatment of recessive dystrophic epidermolysis bullosa. Exp Dermatol. 2016; 25:818-820.","DOI":"10.1111\/exd.13054"},{"key":"123","doi-asserted-by":"crossref","unstructured":"123. Pendaries V, Gasc G, Titeux M, Tonasso L, Mejia JE, Hovnanian A. siRNA-mediated allele-specific inhibition of mutant type VII collagen in dominant dystrophic epidermolysis bullosa. J Invest Dermatol. 2012; 132:1741-1743.","DOI":"10.1038\/jid.2012.11"},{"key":"124","doi-asserted-by":"crossref","unstructured":"124. Morgan CP, Allen DS, Millington-Ward S, O&apos;Dwyer GE, Palfi A, Farrar GJ. A mutation-independent therapeutic strategy for dominant dystrophic epidermolysis bullosa. J Invest Dermatol. 2013; 133:2793-2796.","DOI":"10.1038\/jid.2013.241"},{"key":"125","doi-asserted-by":"crossref","unstructured":"125. Turczynski S, Titeux M, Tonasso L, Decha A, Ishida-Yamamoto A, Hovnanian A. Targeted exon skipping restores type VII collagen expression and anchoring fibril formation in an in vivo RDEB model. J Invest Dermatol. 2016; 136:2387-2395.","DOI":"10.1016\/j.jid.2016.07.029"},{"key":"126","doi-asserted-by":"crossref","unstructured":"126. Murauer EM, Gache Y, Gratz IK, Klausegger A, Muss W, Gruber C, Meneguzzi G, Hintner H, Bauer JW. Functional correction of type VII collagen expression in dystrophic epidermolysis bullosa. J Invest Dermatol. 2011; 131:74-83.","DOI":"10.1038\/jid.2010.249"},{"key":"127","doi-asserted-by":"crossref","unstructured":"127. Peking P, Koller U, Hainzl S, Kitzmueller S, Kocher T, Mayr E, Nystrom A, Lener T, Reichelt J, Bauer JW, Murauer EM. A gene gun-mediated nonviral RNA trans-splicing strategy for Col7a1 repair. Mol Ther Nucleic Acids. 2016; 5:e287.","DOI":"10.1038\/mtna.2016.3"},{"key":"128","doi-asserted-by":"crossref","unstructured":"128. Zingman LV, Park S, Olson TM, Alekseev AE, Terzic A. Aminoglycoside-induced translational read-through in disease: Overcoming nonsense mutations by pharmacogenetic therapy. Clin Pharmacol Ther. 2007; 81:99-103.","DOI":"10.1038\/sj.clpt.6100012"},{"key":"129","doi-asserted-by":"crossref","unstructured":"129. Bedwell DM, Kaenjak A, Benos DJ, Bebok Z, Bubien JK, Hong J, Tousson A, Clancy JP, Sorscher EJ. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat Med. 1997; 3:1280-1284.","DOI":"10.1038\/nm1197-1280"},{"key":"130","doi-asserted-by":"crossref","unstructured":"130. Wagner KR, Hamed S, Hadley DW, Gropman AL, Burstein AH, Escolar DM, Hoffman EP, Fischbeck KH. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann Neurol. 2001; 49:706-711.","DOI":"10.1002\/ana.1023"},{"key":"131","doi-asserted-by":"crossref","unstructured":"131. Christian M, Cermak T, Doyle EL, Schmidt C, Zhang F, Hummel A, Bogdanove AJ, Voytas DF. Targeting DNA double-strand breaks with TAL effector nucleases. Genetics. 2010; 186:757-761.","DOI":"10.1534\/genetics.110.120717"},{"key":"132","doi-asserted-by":"crossref","unstructured":"132. Cermak T, Doyle EL, Christian M, Wang L, Zhang Y, Schmidt C, Baller JA, Somia NV, Bogdanove AJ, Voytas DF. Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res. 2011; 39:e82.","DOI":"10.1093\/nar\/gkr218"},{"key":"133","doi-asserted-by":"crossref","unstructured":"133. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012; 337:816-821.","DOI":"10.1126\/science.1225829"},{"key":"134","unstructured":"134. Yamanaka S, Takahashi K. Induction of pluripotent stem cells from mouse fibroblast cultures. Tanpakushitsu Kakusan Koso. 2006; 51:2346-2351. (in Japanese)"},{"key":"135","doi-asserted-by":"crossref","unstructured":"135. Osborn MJ, Starker CG, McElroy AN, et al. TALEN-based gene correction for epidermolysis bullosa. Mol Ther. 2013; 21:1151-1159.","DOI":"10.1038\/mt.2013.56"},{"key":"136","doi-asserted-by":"crossref","unstructured":"136. Bilousova G, Chen J, Roop DR. Differentiation of mouse induced pluripotent stem cells into a multipotent keratinocyte lineage. J Invest Dermatol. 2011; 131:857-864.","DOI":"10.1038\/jid.2010.364"},{"key":"137","doi-asserted-by":"crossref","unstructured":"137. Itoh M, Kiuru M, Cairo MS, Christiano AM. Generation of keratinocytes from normal and recessive dystrophic epidermolysis bullosa-induced pluripotent stem cells. Proc Natl Acad Sci U S A. 2011; 108:8797-8802.","DOI":"10.1073\/pnas.1100332108"},{"key":"138","doi-asserted-by":"crossref","unstructured":"138. Tolar J, Xia L, Riddle MJ, Lees CJ, Eide CR, McElmurry RT, Titeux M, Osborn MJ, Lund TC, Hovnanian A, Wagner JE, Blazar BR. Induced pluripotent stem cells from individuals with recessive dystrophic epidermolysis bullosa. J Invest Dermatol. 2011; 131:848-856.","DOI":"10.1038\/jid.2010.346"},{"key":"139","doi-asserted-by":"crossref","unstructured":"139. Woodley DT, Wang X, Amir M, Hwang B, Remington J, Hou Y, Uitto J, Keene D, Chen M. Intravenously injected recombinant human type VII collagen homes to skin wounds and restores skin integrity of dystrophic epidermolysis bullosa. J Invest Dermatol. 2013; 133:1910-1913.","DOI":"10.1038\/jid.2013.10"},{"key":"140","doi-asserted-by":"crossref","unstructured":"140. Wang X, Ghasri P, Amir M, Hwang B, Hou Y, Khalili M, Lin A, Keene D, Uitto J, Woodley DT, Chen M. Topical application of recombinant type VII collagen incorporates into the dermal-epidermal junction and promotes wound closure. Mol Ther. 2013; 21:1335-1344.","DOI":"10.1038\/mt.2013.87"},{"key":"141","doi-asserted-by":"crossref","unstructured":"141. Hovnanian A. Systemic protein therapy for recessive dystrophic epidermolysis bullosa: How far are we from clinical translation? J Invest Dermatol. 2013; 133:1719-1721.","DOI":"10.1038\/jid.2013.137"},{"key":"142","doi-asserted-by":"crossref","unstructured":"142. Palazzi X, Marchal T, Chabanne L, Spadafora A, Magnol JP, Meneguzzi G. Inherited dystrophic epidermolysis bullosa in inbred dogs: A spontaneous animal model for somatic gene therapy. J Invest Dermatol. 2000; 115:135-137.","DOI":"10.1046\/j.1523-1747.2000.00031-5.x"},{"key":"143","doi-asserted-by":"crossref","unstructured":"143. South AP, Uitto J. Type VII collagen replacement therapy in recessive dystrophic epidermolysis bullosa-how much, how often? J Invest Dermatol. 2016; 136:1079-1081.","DOI":"10.1016\/j.jid.2016.03.005"},{"key":"144","doi-asserted-by":"crossref","unstructured":"144. Woodley DT, Cogan J, Wang X, Hou Y, Haghighian C, Kudo G, Keene DR, Chen M. De novo anti-type VII collagen antibodies in patients with recessive dystrophic epidermolysis bullosa. J Invest Dermatol. 2014; 134:1138-1140.","DOI":"10.1038\/jid.2013.475"}],"container-title":["Intractable &amp; Rare Diseases Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/6\/1\/6_2017.01005\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T07:01:29Z","timestamp":1498374089000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/6\/1\/6_2017.01005\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":144,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.5582\/irdr.2017.01005","relation":{},"ISSN":["2186-361X","2186-3644"],"issn-type":[{"value":"2186-361X","type":"electronic"},{"value":"2186-3644","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]}}}